Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
We developed a prognostic signature for OS based on 3 previously identified PBBMs for HNSCC treated with ICIs and identified a high-risk group of patients least likely to have survival benefit from ICIs. This signature may improve ICI patient selection and warrants validation in an independent cohort as well as correlation with CPS.
Authors
- Brittany Barber
- George E. Laramore (ORCID: https://orcid.org/0000-0003-2595-2123)
- Qian Wu (ORCID: https://orcid.org/0000-0002-2292-4816)
- Rocco M. Ferrandino (ORCID: https://orcid.org/0000-0003-2092-0296)
- Neal D. Futran (ORCID: https://orcid.org/0000-0002-6380-604X)
- Jay J. Liao (ORCID: https://orcid.org/0000-0003-4679-3037)
- Kevin Ng
- Jenna Voutsinas (ORCID: https://orcid.org/0000-0002-7474-4892)
- Renato Martins (ORCID: https://orcid.org/0000-0001-8105-4219)
- Cassie Pan (ORCID: https://orcid.org/0000-0003-2776-4679)
- Emily Marchiano
- Upendra Parvathaneni (ORCID: https://orcid.org/0000-0003-2370-4492)
- Cristina P. Rodriguez (ORCID: https://orcid.org/0000-0003-3568-2630)
- Neil Panjwani
- Zain H. Rizvi
Institutions
- Virginia Commonwealth University (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- VA Puget Sound Health Care System (US)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1186/s12885-024-13051-6
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Institutes of Health